FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385790911> ?p ?o ?g. }

• W4385790911 abstract "Glioblastoma (GB) is one of the most lethal types of neoplasms. Its biologically aggressive nature and the presence of the blood-brain barrier (BBB) limit the efficacy of standard therapies. Several strategies are currently being developed to both overcome the BBB and deliver drugs site specifically to tumor cells. This work hypothesizes a two-pronged approach to tackle GB: drug repurposing with celecoxib (CXB) and a nanoformulation using ultra-small nanostructured lipid carriers (usNLCs). CXB antitumor druggable activity was inspected bioinformatically and screened in four glioma cell lines aiming at the comparison with temozolomide (TMZ), as standard of care. Delving into formulation design, it was tailored aiming at (i) improving the drug solubility/loading properties, (ii) assigning a thermal-triggerable drug release based on a lipid matrix with a low melting point, and (iii) enhancing the cytotoxic effect by selecting a template targetable to tumor cells. For this purpose, an integrated analysis of the critical material attributes (CMAs), critical process parameters (CPPs), and critical quality attributes (CQAs) was conducted under the umbrella of a quality by design approach. CMAs that demonstrate a high-risk level for the final quality and performance of the usNLCs include the drug solubility in lipids (solid and liquid), the lipid composition (envisioning a thermoresponsive approach), the ratio between lipids (solid vs. liquid), and the surfactant type and concentration. Particle size was shown to be governed by the interaction lipid-surfactant followed by surfactant type. The drug encapsulation did not influence colloidal characteristics, making it a promising carrier for lipophilic drugs. In general, usNLCs exhibited a controlled drug release during the 72 h at 37 °C with a final release of ca. 25%, while at 45 °C this was doubled. The in vitro cellular performance depended on the surfactant type and lipid composition, with the formulations containing a sole solid lipid (Suppocire® NB) and Kolliphor® RH40 as surfactant being the most cytotoxic. usNLCs with an average diameter of ca. 70 nm and a narrow size distribution (PdI lower than 0.2) were yielded, exhibiting high stability, drug protection, sustained and thermo-sensitive release properties, and high cytotoxicity to glioma cells, meeting the suitable CQAs for parenteral administration. This formulation may pave the way to a multi-addressable purpose to improve GB treatment." @default.
• W4385790911 created "2023-08-14" @default.
• W4385790911 creator A5001343827 @default.
• W4385790911 creator A5038444773 @default.
• W4385790911 creator A5070123715 @default.
• W4385790911 creator A5078019318 @default.
• W4385790911 creator A5078391390 @default.
• W4385790911 creator A5081412672 @default.
• W4385790911 date "2023-08-13" @default.
• W4385790911 modified "2023-10-15" @default.
• W4385790911 title "A two-pronged approach against glioblastoma: drug repurposing and nanoformulation design for in situ-controlled release" @default.
• W4385790911 cites W1765159533 @default.
• W4385790911 cites W1991618236 @default.
• W4385790911 cites W2019952326 @default.
• W4385790911 cites W2020164552 @default.
• W4385790911 cites W2028189037 @default.
• W4385790911 cites W2035682431 @default.
• W4385790911 cites W2047212821 @default.
• W4385790911 cites W2063346783 @default.
• W4385790911 cites W2067786443 @default.
• W4385790911 cites W2078532650 @default.
• W4385790911 cites W2089300023 @default.
• W4385790911 cites W2096439168 @default.
• W4385790911 cites W2121963092 @default.
• W4385790911 cites W2126642373 @default.
• W4385790911 cites W2131347449 @default.
• W4385790911 cites W2142395144 @default.
• W4385790911 cites W2145692162 @default.
• W4385790911 cites W2207931075 @default.
• W4385790911 cites W2280735232 @default.
• W4385790911 cites W2392045628 @default.
• W4385790911 cites W2508112086 @default.
• W4385790911 cites W2522590257 @default.
• W4385790911 cites W2537679995 @default.
• W4385790911 cites W2586783706 @default.
• W4385790911 cites W258735800 @default.
• W4385790911 cites W2748209289 @default.
• W4385790911 cites W2768618412 @default.
• W4385790911 cites W2777884179 @default.
• W4385790911 cites W2792617550 @default.
• W4385790911 cites W2800814277 @default.
• W4385790911 cites W2801591047 @default.
• W4385790911 cites W2806362696 @default.
• W4385790911 cites W2809082812 @default.
• W4385790911 cites W2811076332 @default.
• W4385790911 cites W2890896123 @default.
• W4385790911 cites W2894216837 @default.
• W4385790911 cites W2897366366 @default.
• W4385790911 cites W2898146268 @default.
• W4385790911 cites W2901190183 @default.
• W4385790911 cites W2942340216 @default.
• W4385790911 cites W2974855993 @default.
• W4385790911 cites W3007210350 @default.
• W4385790911 cites W3009537504 @default.
• W4385790911 cites W3019914032 @default.
• W4385790911 cites W3033732135 @default.
• W4385790911 cites W3040237634 @default.
• W4385790911 cites W3043142327 @default.
• W4385790911 cites W3079252823 @default.
• W4385790911 cites W3083551364 @default.
• W4385790911 cites W3111615455 @default.
• W4385790911 cites W3122142309 @default.
• W4385790911 cites W3129178541 @default.
• W4385790911 cites W3136298349 @default.
• W4385790911 cites W3138130200 @default.
• W4385790911 cites W3176876419 @default.
• W4385790911 cites W3186062289 @default.
• W4385790911 cites W3211402536 @default.
• W4385790911 cites W4206965224 @default.
• W4385790911 cites W4211220688 @default.
• W4385790911 cites W4293767581 @default.
• W4385790911 doi "https://doi.org/10.1007/s13346-023-01379-8" @default.
• W4385790911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37574500" @default.
• W4385790911 hasPublicationYear "2023" @default.
• W4385790911 type Work @default.
• W4385790911 citedByCount "0" @default.
• W4385790911 crossrefType "journal-article" @default.
• W4385790911 hasAuthorship W4385790911A5001343827 @default.
• W4385790911 hasAuthorship W4385790911A5038444773 @default.
• W4385790911 hasAuthorship W4385790911A5070123715 @default.
• W4385790911 hasAuthorship W4385790911A5078019318 @default.
• W4385790911 hasAuthorship W4385790911A5078391390 @default.
• W4385790911 hasAuthorship W4385790911A5081412672 @default.
• W4385790911 hasBestOaLocation W43857909111 @default.
• W4385790911 hasConcept C103637391 @default.
• W4385790911 hasConcept C147789679 @default.
• W4385790911 hasConcept C155574463 @default.
• W4385790911 hasConcept C171250308 @default.
• W4385790911 hasConcept C178790620 @default.
• W4385790911 hasConcept C185592680 @default.
• W4385790911 hasConcept C187530423 @default.
• W4385790911 hasConcept C18903297 @default.
• W4385790911 hasConcept C192562407 @default.
• W4385790911 hasConcept C199529486 @default.
• W4385790911 hasConcept C2780035454 @default.
• W4385790911 hasConcept C2780449318 @default.
• W4385790911 hasConcept C519536355 @default.
• W4385790911 hasConcept C71924100 @default.
• W4385790911 hasConcept C86803240 @default.
• W4385790911 hasConcept C98274493 @default.

• next